These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 8996147)

  • 1. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
    Lee WR; Hanks GE; Hanlon A
    J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.
    Hanlon AL; Diratzouian H; Hanks GE
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):297-303. PubMed ID: 12023133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.
    Pinover WH; Horwitz EM; Hanlon AL; Uzzo RG; Hanks GE
    Cancer; 2003 Feb; 97(4):1127-33. PubMed ID: 12569615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
    Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.
    Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Polkinghorn W; McBride S; Kollmeier M; Yamada Y; Zelefsky MJ
    Eur Urol; 2015 Jun; 67(6):1009-1016. PubMed ID: 25308970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer.
    Hanlon AL; Horwitz EM; Hanks GE; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):43-52. PubMed ID: 14697419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.
    Sengupta S; Blute ML; Bagniewski SM; Myers RP; Bergstralh EJ; Leibovich BC; Zincke H
    J Urol; 2006 May; 175(5):1684-90; discussion 1690. PubMed ID: 16600730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA doubling time post radiation: the effect of neoadjuvant androgen ablation.
    Tyldesley S; Coldman A; Pickles T;
    Can J Urol; 2004 Aug; 11(4):2316-21. PubMed ID: 15460601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
    Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database.
    Kim-Sing C; Pickles T;
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):463-9. PubMed ID: 15380580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.